These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 10916754)

  • 1. Tumor necrosis factor-alpha augments tumor effects in isolated hepatic perfusion with melphalan in a rat sarcoma model.
    van Ijken MG; van Etten B; de Wilt JH; van Tiel ST; ten Hagen TL; Eggermont AM
    J Immunother; 2000; 23(4):449-55. PubMed ID: 10916754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic effects of TNF-alpha and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathological, immunohistochemical and electron microscopical study.
    Nooijen PT; Manusama ER; Eggermont AM; Schalkwijk L; Stavast J; Marquet RL; de Waal RM; Ruiter DJ
    Br J Cancer; 1996 Dec; 74(12):1908-15. PubMed ID: 8980389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The αVβ3/αVβ5 integrin inhibitor cilengitide augments tumor response to melphalan isolated limb perfusion in a sarcoma model.
    Ten Hagen TL; Seynhaeve AL; de Wiel-Ambagtsheer Ga; de Bruijn EA; van Tiel ST; Ruegg C; Meyring M; Grell M; Goodman SL; Eggermont AM
    Int J Cancer; 2013 Jun; 132(11):2694-704. PubMed ID: 23152080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Degree of tumour vascularity correlates with drug accumulation and tumour response upon TNF-alpha-based isolated hepatic perfusion.
    van Etten B; de Vries MR; van IJken MG; Lans TE; Guetens G; Ambagtsheer G; van Tiel ST; de Boeck G; de Bruijn EA; Eggermont AM; ten Hagen TL
    Br J Cancer; 2003 Jan; 88(2):314-9. PubMed ID: 12610519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isolated limb perfusion with melphalan, tumour necrosis factor-alpha and oncolytic vaccinia virus improves tumour targeting and prolongs survival in a rat model of advanced extremity sarcoma.
    Pencavel TD; Wilkinson MJ; Mansfield DC; Khan AA; Seth R; Karapanagiotou EM; Roulstone V; Aguilar RJ; Chen NG; Szalay AA; Hayes AJ; Harrington KJ
    Int J Cancer; 2015 Feb; 136(4):965-76. PubMed ID: 24978211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isolated limb perfusion for extremity soft-tissue sarcomas, in-transit metastases, and other unresectable tumors: credits, debits, and future perspectives.
    Eggermont AM; ten Hagen TL
    Curr Oncol Rep; 2001 Jul; 3(4):359-67. PubMed ID: 11389822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic antitumour effect of recombinant human tumour necrosis factor alpha with melphalan in isolated limb perfusion in the rat.
    Manusama ER; Nooijen PT; Stavast J; Durante NM; Marquet RL; Eggermont AM
    Br J Surg; 1996 Apr; 83(4):551-5. PubMed ID: 8665257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial.
    Eggermont AM; Schraffordt Koops H; Liénard D; Kroon BB; van Geel AN; Hoekstra HJ; Lejeune FJ
    J Clin Oncol; 1996 Oct; 14(10):2653-65. PubMed ID: 8874324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic leakage and side effects of tumor necrosis factor alpha administered via isolated limb perfusion can be manipulated by flow rate adjustment.
    Sorkin P; Abu-Abid S; Lev D; Gutman M; Aderka D; Halpern P; Setton A; Kudlik N; Bar-On J; Rudich V
    Arch Surg; 1995 Oct; 130(10):1079-84. PubMed ID: 7575120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic antitumor activity of histamine plus melphalan in isolated limb perfusion: preclinical studies.
    Brunstein F; Hoving S; Seynhaeve AL; van Tiel ST; Guetens G; de Bruijn EA; Eggermont AM; ten Hagen TL
    J Natl Cancer Inst; 2004 Nov; 96(21):1603-10. PubMed ID: 15523089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats.
    de Wilt JH; Manusama ER; van Tiel ST; van Ijken MG; ten Hagen TL; Eggermont AM
    Br J Cancer; 1999 Apr; 80(1-2):161-6. PubMed ID: 10389992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic antitumor response of interleukin 2 with melphalan in isolated limb perfusion in soft tissue sarcoma-bearing rats.
    Hoving S; Brunstein F; aan de Wiel-Ambagtsheer G; van Tiel ST; de Boeck G; de Bruijn EA; Eggermont AM; ten Hagen TL
    Cancer Res; 2005 May; 65(10):4300-8. PubMed ID: 15899822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience.
    Eggermont AM; Schraffordt Koops H; Klausner JM; Kroon BB; Schlag PM; Liénard D; van Geel AN; Hoekstra HJ; Meller I; Nieweg OE; Kettelhack C; Ben-Ari G; Pector JC; Lejeune FJ
    Ann Surg; 1996 Dec; 224(6):756-64; discussion 764-5. PubMed ID: 8968230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Value of continuous leakage monitoring with radioactive iodine-131-labeled human serum albumin during hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan.
    van Ginkel RJ; Limburg PC; Piers DA; Koops HS; Hoekstra HJ
    Ann Surg Oncol; 2002 May; 9(4):355-63. PubMed ID: 11986187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High dose tumor necrosis factor-alpha and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation.
    Gutman M; Inbar M; Lev-Shlush D; Abu-Abid S; Mozes M; Chaitchik S; Meller I; Klausner JM
    Cancer; 1997 Mar; 79(6):1129-37. PubMed ID: 9070490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic antitumour effect of TNF-SAM2 with melphalan and doxorubicin in isolated limb perfusion in rats.
    de Wilt JH; Soma G; ten Hagen TL; Kanou J; Takagi K; Nooijen PT; Seynhaevel AL; Eggermont AM
    Anticancer Res; 2000; 20(5B):3491-6. PubMed ID: 11131652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Isolated limb perfusion with tumor necrosis factor for malignancies of the limbs].
    Abu-Abid S; Gutman M; Lev D; Inbar M; Chaitchik S; Sorkine P; Rudick V; Meller I; Klausner JM
    Harefuah; 1996 Oct; 131(7-8):227-32, 296, 295. PubMed ID: 8940515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absence of severe systemic toxicity after leakage-controlled isolated limb perfusion with tumor necrosis factor-alpha and melphalan.
    Vrouenraets BC; Kroon BB; Ogilvie AC; van Geel AN; Nieweg OE; Swaak AJ; Eggermont AM
    Ann Surg Oncol; 1999 Jun; 6(4):405-12. PubMed ID: 10379864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complications of combined radiotherapy and isolated limb perfusion with tumor necrosis factor alpha +/- interferon gamma and melphalan in patients with irresectable soft tissue tumors.
    Vrouenraets BC; Keus RB; Nieweg OE; Kroon BB
    J Surg Oncol; 1997 Jun; 65(2):88-94. PubMed ID: 9209519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of isolated limb perfusion with recombinant human tumor necrosis factor α and melphalan in locally advanced extremity soft tissue sarcoma.
    Jakob J; Hohenberger P
    Cancer; 2016 Sep; 122(17):2624-32. PubMed ID: 27197621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.